Larimar Therapeutics, Inc.

Approval AI-extracted

nomlabofusp

Friedreich's ataxia

Resolved

7days ago

Approval decision · Jun 30, 2026

What's at stake A final FDA approval decision on nomlabofusp for Friedreich's ataxia is expected Jun 30, 2026.

Primary source · SEC 8-K verified 14h ago

“Planned BLA submission seeking accelerated approval on track for June 2026; U.S. launch targeted for first-half 2027, if approved.”

2 sources on file.

Link copied ✓